You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞科生物-B(02179.HK)公開發售獲超額認購10.65倍 發售價每股24.8港元
格隆匯 03-30 07:41

格隆匯3月30日丨瑞科生物-B(02179.HK)發佈公吿,公司全球發售3085.45萬股股份,其中香港發售股份308.55萬股,國際發售股份2776.9萬股,另有15%超額配股權;發售價每股發售股份24.80港元,每手買賣單位500股;摩根士丹利、招銀國際及中信證券為聯席保薦人;預期股份將於2022年3月31日於聯交所主板掛牌上市。

根據香港公開發售項下初步提呈發售的香港發售股份已獲小幅超額認購。合共接獲7853份有效申請,認購合共3286.6萬股香港發售股份,相當於根據香港公開發售初步可供認購的H股總數約10.65倍。根據國際發售項下初步提呈發售的發售股份已獲小幅超額認購,相當於根據國際發售初步可供認購的國際發售股份總數的約1.39倍。基於發售價每股24.80港元,根據相關基石投資協議,公司的基石投資者已認購合共1671.85萬股H股。

按發售價每股24.80港元計算,公司將自全球發售收取的所得款項淨額估計約為6.724億港元(假設超額配售權未獲行使)。公司擬將所得款項淨額47.3%分配予集團HPV疫苗管線(包括集團的核心產品,即REC603)的研發、生產及商業化;17.7%將分配予集團的新冠肺炎候選疫苗ReCOV;21.1%將分配至其他候選疫苗(包括重組帶狀皰疹疫苗REC610、結核病疫苗REC606及REC607、重組四價流感疫苗REC617及重組手足口病四價疫苗REC605)的臨牀前及臨牀研究、註冊;6.7%將分配至進一步加強集團的研發能力及提高營運效率;7.2%將分配用於營運資金及其他一般公司用途。倘超額配售權獲悉數行使,則公司將就因超額配售權獲行使而將予發行及配發的462.8萬股額外發售股份收取額外所得款項淨額約1.102億港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account